Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.

Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR Jr.

Neuropsychopharmacology. 1999 Dec;21(6):683-93.

2.

The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study.

Hansen ES, Hasselbalch S, Law I, Bolwig TG.

Int J Neuropsychopharmacol. 2002 Mar;5(1):1-10.

PMID:
12057027
3.

Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression.

Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter LR Jr.

Arch Gen Psychiatry. 2002 Mar;59(3):250-61.

PMID:
11879163
4.

Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr.

Am J Psychiatry. 2003 Mar;160(3):522-32.

PMID:
12611834
5.

Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.

Kwon JS, Kim JJ, Lee DW, Lee JS, Lee DS, Kim MS, Lyoo IK, Cho MJ, Lee MC.

Psychiatry Res. 2003 Jan 20;122(1):37-47.

PMID:
12589881
6.

Effects of behavioral therapy or pharmacotherapy on brain glucose metabolism in subjects with obsessive-compulsive disorder as assessed by brain FDG PET.

Apostolova I, Block S, Buchert R, Osen B, Conradi M, Tabrizian S, Gensichen S, Schröder-Hartwig K, Fricke S, Rufer M, Weiss A, Hand I, Clausen M, Obrocki J.

Psychiatry Res. 2010 Nov 30;184(2):105-16. doi: 10.1016/j.pscychresns.2010.08.012. Epub 2010 Oct 14.

PMID:
20947317
7.

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.

Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ.

J Am Acad Child Adolesc Psychiatry. 2000 Sep;39(9):1096-103.

PMID:
10986805
8.

Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently.

Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR Jr.

Biol Psychiatry. 2001 Aug 1;50(3):159-70.

PMID:
11513814
9.

Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls.

Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE.

Arch Gen Psychiatry. 1987 Mar;44(3):211-8. Erratum in: Arch Gen Psychiatry 1987 Sep;44(9):800.

PMID:
3493749
10.

Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder.

Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME.

Arch Gen Psychiatry. 1996 Feb;53(2):109-13.

PMID:
8629886
11.

Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study.

Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA.

Neuropsychopharmacology. 2002 Nov;27(5):782-91.

12.

FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder.

Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr.

Psychiatry Res. 1998 Nov 9;84(1):1-6.

PMID:
9870412
13.

Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study.

Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, Kosaka J, Arakawa R, Fujimura Y, Ota M, Takano A, Fukui K, Nakayama K, Suhara T.

Neuroimage. 2010 Jan 1;49(1):121-6. doi: 10.1016/j.neuroimage.2009.07.069. Epub 2009 Aug 4.

PMID:
19660554
14.

Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.

Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, Seedat S, Stein DJ.

BMC Psychiatry. 2004 Oct 14;4:30.

15.

Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.

Bolton J, Moore GJ, MacMillan S, Stewart CM, Rosenberg DR.

J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):903-6.

PMID:
11501689
16.

Cerebral glucose metabolism in obsessive-compulsive hoarding.

Saxena S, Brody AL, Maidment KM, Smith EC, Zohrabi N, Katz E, Baker SK, Baxter LR Jr.

Am J Psychiatry. 2004 Jun;161(6):1038-48.

PMID:
15169692
18.

Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy.

Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL.

Arch Gen Psychiatry. 1992 Sep;49(9):690-4.

PMID:
1514873
19.

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, Emslie G, Carpenter D.

J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S19-29.

PMID:
12880497
20.

Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.

Gilbert AR, Moore GJ, Keshavan MS, Paulson LA, Narula V, Mac Master FP, Stewart CM, Rosenberg DR.

Arch Gen Psychiatry. 2000 May;57(5):449-56.

PMID:
10807485
Items per page

Supplemental Content

Write to the Help Desk